The local delivery of antiproliferative agents to inhibit neointimal growth is not specific to vascular smooth muscle cells (VSMC) and delays reendothelialization and vascular healing. This investigation was intended to evaluate the effect of luminal delivery of a VSMC-specific aptamer on endothelial healing. The impact of an RNA aptamer (Apt 14) was first examined on the migration and proliferation of primary cultured porcine aortic endothelial cells (ECs) in response to in vitro scratch wound injury. We further evaluated the impact of Apt 14 on reendothelialization when delivered locally in a swine iliofemoral injury model. Although Apt 14 did not affect EC migration and proliferation, in vitro results confirmed that paclitaxel significan...
Intimal hyperplasia (IH) represents a major challenge following cardiovascular interventions. While ...
Vascular restenosis is affecting 30-40% of patients treated by percutaneous coronary angioplasty (PT...
Non-specific cytotoxins, including paclitaxel and sirolimus analogues, currently utilized as anti-re...
Vascular walls change their dimension and mechanical properties in response to injury such as balloo...
Objective: We compared local vessel healing and inflammatory responses associated with nonoverlappin...
Purpose: To investigate the effect of paclitaxel delivered into the adventitia of pig femoral arteri...
Objective: Invasive coronary interventions can fail due to intimal hyperplasia and restenosis. Endot...
Drugs currently approved to coat stents used in percutaneous coronary interventions do not discrimin...
Aims In-stent restenosis remains a serious problem after the implantation of drug-eluting stents, wh...
Objectives:Vascular endothelial growth factor (VEGF) is reported to be a potent and specific mitogen...
ObjectiveHigh restenosis rates are a limitation of peripheral vascular interventions. Previous studi...
Abstract: Late thrombosis and neointima proliferation after paclitaxel-eluting stents implanting may...
Here we investigated how a coating of intravascular balloon with paclitaxel (drug-coated balloon; DC...
Background: Drug-eluting stents (DES) have been introduced successfully in clinical practice to prev...
Objectives. To observe the effect of avβ3 single-stranded (ss) DNA on proliferation and migration of...
Intimal hyperplasia (IH) represents a major challenge following cardiovascular interventions. While ...
Vascular restenosis is affecting 30-40% of patients treated by percutaneous coronary angioplasty (PT...
Non-specific cytotoxins, including paclitaxel and sirolimus analogues, currently utilized as anti-re...
Vascular walls change their dimension and mechanical properties in response to injury such as balloo...
Objective: We compared local vessel healing and inflammatory responses associated with nonoverlappin...
Purpose: To investigate the effect of paclitaxel delivered into the adventitia of pig femoral arteri...
Objective: Invasive coronary interventions can fail due to intimal hyperplasia and restenosis. Endot...
Drugs currently approved to coat stents used in percutaneous coronary interventions do not discrimin...
Aims In-stent restenosis remains a serious problem after the implantation of drug-eluting stents, wh...
Objectives:Vascular endothelial growth factor (VEGF) is reported to be a potent and specific mitogen...
ObjectiveHigh restenosis rates are a limitation of peripheral vascular interventions. Previous studi...
Abstract: Late thrombosis and neointima proliferation after paclitaxel-eluting stents implanting may...
Here we investigated how a coating of intravascular balloon with paclitaxel (drug-coated balloon; DC...
Background: Drug-eluting stents (DES) have been introduced successfully in clinical practice to prev...
Objectives. To observe the effect of avβ3 single-stranded (ss) DNA on proliferation and migration of...
Intimal hyperplasia (IH) represents a major challenge following cardiovascular interventions. While ...
Vascular restenosis is affecting 30-40% of patients treated by percutaneous coronary angioplasty (PT...
Non-specific cytotoxins, including paclitaxel and sirolimus analogues, currently utilized as anti-re...